New cytotoxic agents

Cancer Treatment Reviews

Volumn 23, Issue SUPPL. 1, 1997, Pages

  Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADOZELESIN; ANTHRACYCLINE; ANTIMETABOLITE; CAPECITABINE; CARZELESIN; CEMADOTIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LIPOSOME; NAVELBINE; OXALIPLATIN; PACLITAXEL; PACLITAXEL DERIVATIVE; RALTITREXED; SATRAPLATIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER REGRESSION; CLINICAL TRIAL; DIARRHEA; FEVER; FLU LIKE SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; META ANALYSIS; METASTASIS; MICROTUBULE ASSEMBLY; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0030721669     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90008-6     Document Type: Article

References (28)

1. Kalla, S., Bourgeois, H., Guia, G., et al. (1996) Docetaxel in combination with doxonbicin as first line chemotherapy of metastatic breast cancer: a phase I dose-finding study. Final results. Ann. Oncol. 7: 124.
2. Fumoleau, P., Chevallier, B., Kerbrat, P., et al. (1995) Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res. Treat. 33: 39-46.
3. Seno, M., Adachi, I., Wetenebe, T., et al. (1997) A phase I/II study of docetaxel in combination with continuous infusion of fluorourecil in patients with advanced or recurrent breast cancer. Proc. ASCO 16: 189a.
4. Vasey, P. A., Twelves, C., Roche, H., et al. A phase I-II study of docetaxel plus cyclophosphamide as first-line chemotherapy in metastatic breast cancer patients. EWOC 5, Motteret France, January 1997.
5. Schrijvers, D., Prank, L., Schellens, J., et al. (1996) A phase I and pharmacokinetic study of docetaxel and ifosfamide in patients with advanced solid tumours. Ann. Oncol. 7: 125.
6. Peacock, N., Rodriguet, G., Smith, L., et al. (1996) A phase I study of docetaxel and FU combination chemotherapy in patients with advanced solid tumours. Proc. ASCO 15: 1190.
7. Kerger, J., Van Den Neste, E., de Valeriola, D., et al. (1996) Phase I clinical study of docetaxel in combination with continuous infusion fluorourecil in patients with advanced solid tumours. Ann. Oncol. 7: 130.
8. Verweij, J., Plenting, A. S. T., Van den Burg, M. E. L., et al. (1994) A phase I study of docetaxel and cisplatin in patients with solid tumours. Proc. ASCO 13: 148.
9. Couteau, C., Yakendji, K., Terret, C., et al. (1996) Taxotere (docetaxel) and CPT11 (irinotecan): phase I trials. Bull Cancer 83: 3-10.
10. Tomiak, E., Piccart, M. J., Kerger, J., et al. (1994) Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J. Clin. Oncol. 12: 1458-1467.
11. Bonadonna, G., Veronesi, U., Brambilla, C., et al. (1990) Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. J. Natl. Cancer Inst. 82: 1539-1545.
12. Wright, C., Angus, B., Nicholson, S., et al. (1989) Expression of C-erb B2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 4P: 2087.
13. Nicholson, S., Wright, C., Sainsbury, J. R., et al. (1990) Epidermal growth factor receptor as a marker for poor prognosis in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10: 599-604.
14. Soubeyran, I., Quenel, N., Mauriac, L., et al. (1996) Variation of hormone receptor, pS2, C-erb B2 and GSTpi contents in breast carcinoma under tamoxifen: A study of 74 cases. Brit. J. Cancer 73: 735-743.
15. Leitzel, K., Teremoto, Y., Sampson, E., et al. (1992) Elevated soluble C-erb B2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J. Clin. Oncol. 10: 1436-1443.
16. Allred, D. C., Clark, G. M., Molina, R., et al. (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23: 974-979.
17. Gusterson, B. A. (1992) Prognostic importance of C-erb B2 expression in breast cancer. J. Clin. Oncol. 10: 1049.
18. Carmichael, J., Possinger, K., Phillip, P., et al. (1995) Advanced breast cancer: a phase II clinical trial with gemcitabine. J. Clin. Oncol. 13: 2731-2736.
19. Spielmann, M., Pouillert, P., Espie, M., et al. (1996) Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Ann. Oncol. 7: 23.
20. Blackstein, M., Vogel, C. L., Aenbinter, R., et al. (1996) Phase II study of gemcitabine in patients with metastatic breast cancer. Proc. ASCO 15: 117.
21. Smith, I. E. (1996) Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug? Ann. Oncol. 7: 771-772.
22. Huan, S., Pazdur, R., Singhakowinta, A., et al. (1989) Low-dose continuous infusion 5-fluorourecil. Evaluation in advanced breast carcinoma. Cancer 63: 419-422.
23. Jabboury, K., Holmes, F. A. & Hortobagyi, G. (1989) 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793-797.
24. Hansen, R. M. (1991) 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest. 9: 637-642.
25. Chang, A.Y., Most, C. & Pandya, K. J. (1989) Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am. J. Clin. Oncol. 12: 453-455.
26. Regazzoni, S., Pesce, G., Marini, G., et al. (1996) Low-dose continuous intravenous infusion of 5-fluorourcil for metastatic breast cancer. Ann. Oncol. 7: 807-813.
27. Goldschmidt, E., Bonneterre, J., Fumoleau, P. et al. (1997) A phase II study of topotecan on a daily x5 schedule as second-line agent therapy in patients with advanced breast cancer. Pro. ASCO 16: 171a.
28. Taguchi, T. (1991) Topoisomerase inhibitor as chemotherapeutic drug - clinical point of view. Gan To Kagaku Ryoho 18: 1574-1578.